CRF Health Launches Updated Platform
Plymouth Meeting, PA – 19 June 2017: CRF Health, global provider of patient-centered eSource technology and service solutions for the life sciences industry, launched version 2 of TrialConsent™, offering updates to the industry’s electronic informed consent solution with a fully embedded design tool.
The solution promotes better comprehension, compliance, and retention rates while reducing regulatory risk. TrialConsent™ 2.0 marks an advance in electronic informed consent by offering an improved user interface with enhanced navigation for participants and site personnel. Sponsors, Institutional Review Boards, Ethics Committees and research sites also benefit from the improved collaboration offered by the solution and much simplified review process.
Rachael Wyllie, CEO commented, “CRF Health is committed to simplifying the path to approval, streamlining complex processes and delivering reliable results for superior clinical trial outcomes. The forward-thinking architecture behind TrialConsent 2.0 allows the platform to be fully integrated with an existing eCOA solution or delivered as a stand-alone solution, simplifying and providing consistency, control and flexibility to the informed consent process. Comprehensive reporting enables study teams and ethics committees to monitor the consent status of sites and participants, track and analyze compliance and ultimately make smarter decisions. We firmly believe this advancement represents a step change in the way Informed Consent can be managed throughout its lifecycle.”
For more information on CRF Health's TrialConsent™ solution, please visit www.crfhealth.com.
About CRF Health
CRF Health is a provider of patient-centered eSource and telemedicine solutions for the life sciences industry. With experience in more than 800 clinical trials, over 100 languages, and across 74 countries, CRF Health’s TrialMax® platform demonstrates the industry’s data accuracy, patient and site compliance, and patient retention. Its recent acquisition of mHealth provider Entra Health, has allowed CRF Health to extend the connectivity of its existing technology to now include cloud-based remote patient monitoring, telehealth, data exchange, and analytics.
Contact: media@crfhealth.com, +1 267.498.2350
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
